Document is current
Any future updates will be listed below
-
Authors
Giudice, Jonathan https://orcid.org/0000-0002-0775-9146
Brauer, Daniel D. https://orcid.org/0000-0001-6974-3476
Zoltek, Madeline https://orcid.org/0000-0001-7988-7764
Vázquez-Maldonado, Angel L.
Dadina, Neville
Kelly, Mark https://orcid.org/0000-0003-3209-1018
Schepartz, Alanna https://orcid.org/0000-0003-2127-3932
-
Funding
Funding for this research was provided by:
National Science Foundation (CHE-2203903, DGE 2146752, CHE-221324)
U.S. Department of Health & Human Services | National Institutes of Health (GM134963, 1S10OD023455-01A1)
- License Information
-
More Information
Article History
Received: 5 April 2024
Accepted: 6 May 2025
First Online: 8 July 2025
Competing interests
: A.S. receives research support from Merck, Amgen and Novo Nordisk. A.S. is a science advisory board member for both Lycia and Evozyne. The remaining authors declare no competing interests.
